Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rongbin Li

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Cellular and Molecular Gastroenterology and Hepatology|April 30, 2025
CMTM3 Promotes Colitis-associated Carcinogenesis Via CLTC Stabilization and Modulation of VE-cadherinRongbin Li, Yuan Liu, Qiyao Liu, et al.
Journal of Translational Medicine|January 22, 2025
Firsekibart in acute gouty arthritisYu Xue, Tianshu Chu, Jiankang Hu, et al.
Science (New York, N.Y.)|August 1, 2020
Exceptional plasticity in the bulk single-crystalline van der Waals semiconductor InSeTian-Ran Wei, Min Jin, Yuecun Wang, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Systematic characterization of protein structural features of alternative splicing isoforms using AlphaFold 2Yuntao Yang, Yuhan Xie, Zhao Li, et al.
ACR Open Rheumatology|November 7, 2025
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled TrialYiyun Yu, Yu Xue, Jiankang Hu, et al.
Nucleic Acids Research|November 12, 2024
ASpdb: an integrative knowledgebase of human protein isoforms from experimental and AI-predicted structuresYuntao Yang, Himansu Kumar, Yuhan Xie, et al.
Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.
Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
BMC Medicine|December 8, 2025
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trialYue Cheng, Honghu Tang, Yufeng Qing, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cellular and Molecular Gastroenterology and Hepatology|April 30, 2025
CMTM3 Promotes Colitis-associated Carcinogenesis Via CLTC Stabilization and Modulation of VE-cadherinRongbin Li, Yuan Liu, Qiyao Liu, et al.
Journal of Translational Medicine|January 22, 2025
Firsekibart in acute gouty arthritisYu Xue, Tianshu Chu, Jiankang Hu, et al.
Science (New York, N.Y.)|August 1, 2020
Exceptional plasticity in the bulk single-crystalline van der Waals semiconductor InSeTian-Ran Wei, Min Jin, Yuecun Wang, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Systematic characterization of protein structural features of alternative splicing isoforms using AlphaFold 2Yuntao Yang, Yuhan Xie, Zhao Li, et al.
ACR Open Rheumatology|November 7, 2025
Firsekibart as a Prophylactic Treatment for Acute Gout Flare in Participants Initiating Urate-Lowering Therapy: A Phase 2, Randomized, Open-Label, Multicenter, Active-Controlled TrialYiyun Yu, Yu Xue, Jiankang Hu, et al.
Nucleic Acids Research|November 12, 2024
ASpdb: an integrative knowledgebase of human protein isoforms from experimental and AI-predicted structuresYuntao Yang, Himansu Kumar, Yuhan Xie, et al.
Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.
Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
BMC Medicine|December 8, 2025
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trialYue Cheng, Honghu Tang, Yufeng Qing, et al.
Pageof 5